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Stephen Bianchi 2, David G. Kiely 2 and Andrew J. Swift 1,3*
1 Department of Infection, Immunity and Cardiovascular Disease, University of Shefield, Royal Hallamshire Hospital, 
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Purpose: It is postulated that ILD causes PA dilatation independent of the presence of 
pulmonary hypertension (PH), so the use of PA size to screen for PH is not recommended. 
The aims of this study were to investigate the association of PA size with the presence and 
severity of ILD and to assess the diagnostic accuracy of PA size for detecting PH.
Methods: Incident patients referred to a tertiary PH centre underwent baseline thoracic CT, 
MRI and right heart catheterisation (RHC). Pulmonary artery diameter was measured on CT 
pulmonary angiography and pulmonary arterial areas on MRI. A thoracic radiologist scored 
the severity of ILD on CT from 0 to 4, 0 = absent, 1 = 1–25%, 2 = 26–50%, 3 = 51–75%, 
and 4 = 76–100% extent of involvement. Receiver operating characteristic analysis and linear 
regression were employed to assess diagnostic accuracy and independent associations of 
PA size.
Results: 110 had suspected PH due to ILD (age 65 years (SD 13), M:F 37:73) and 379 
had suspected PH without ILD (age 64 years (SD 13), M:F 161:218). CT derived main PA 
diameter was accurate for detection of PH in patients both with and without ILD - AUC 
0.873, p =< 0.001, and AUC 0.835, p =< 0.001, respectively, as was MRI diastolic PA area, 
AUC 0.897, p =< 0.001, and AUC 0.857, p =< 0.001, respectively Significant correlations 
were identified between mean pulmonary arterial pressure (mPAP) and PA diameter in ILD (r 
= 0.608, p < 0.001), and non-ILD cohort (r = 0.426, p < 0.001). PA size was independently 
associated with mPAP (p < 0.001) and BSA (p = 0.001), but not with forced vital capacity % 
predicted (p = 0.597), Transfer factor of the lungs for carbon monoxide (TLCO) % predicted 
(p = 0.321) or the presence of ILD on CT (p = 0.905). The severity of ILD was not associated 
with pulmonary artery dilatation (r = 0.071, p = 0.459).
Conclusions: Pulmonary arterial pressure elevation leads to pulmonary arterial dilation, which 
is not independently influenced by the presence or severity of ILD measured by FVC, TLCO, 
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or disease severity on CT. Pulmonary arterial diameter has diagnostic value in patients with 
or without ILD and suspected PH.
Keywords: interstitial lung disease, computed tomography (cT) scanning, right heart catheterisation, pulmonary 
artery diameter, pulmonary hypertension
inTrODUcTiOn
Pulmonary hypertension (PH) is deined on right heart 
catheterisation (RHC), as a resting mean pulmonary artery 
pressure (mPAP) greater than or equal to 25 mmHg (1, 2). PH 
commonly complicates lung disease and chronic hypoxia, such as 
interstitial lung disease (ILD). When present in lung disease, PH 
is associated with a poor outcome (3).
CT is used to diagnose and phenotype suspected ILD, and is 
oten part of the workup of patients with unexplained breathlessness 
and suspected PH (4). Dilatation of the main pulmonary artery 
(PA) or major branch vessels has been identiied as markers of the 
presence of PH and is oten the irst imaging inding to suggest the 
diagnosis (5–9). As CT is commonly used in the investigation of 
patients with ILD, it would be useful to use the pulmonary arterial 
size to screen for the presence of pulmonary hypertension. Routine 
CT pulmonary angiography is performed without ECG gating. 
Pulmonary arterial size changes during the cardiac cycle. MRI 
is typically gated to the cardiac cycle and allows assessment of 
pulmonary arterial size at both systole and diastole. Some authors 
have suggested that in the presence of established lung ibrosis, 
the main PA diameter is not accurate for estimation of mean 
pulmonary arterial pressure as dilatation of the main PA develops 
in patients with pulmonary ibrosis in the absence of PH (5, 10).
he aim of this study was to investigate the role of main 
pulmonary arterial size in patients with ILD and suspected 
pulmonary hypertension. Firstly, by investigating the factors 
associated with main pulmonary arterial dilatation, including 
markers of disease severity in interstitial lung disease. Secondly, 
to compare the diagnostic accuracy of PA size in patients with 
suspected pulmonary hypertension with and without ILD.
MeThODs
Patients
Consecutive patients who were referred to a pulmonary 
hypertension centre from 24 April 2012 to 30 March 2016 were 
identiied from the ASPIRE registry (3). Patients with a CT scan 
within 90 days of MRI and RHC were included. In order to meet 
inclusion criteria, a diagnostic quality CT pulmonary angiogram 
(CTPA) with a slice thickness of less than 5 mm was required. 
Patients underwent systemic evaluation as part of their routine 
clinical workup, which included clinical review, multi-modality 
imaging and lung function testing.
he aetiology of pulmonary hypertension was decided at a multi-
disciplinary team meeting, based upon review of radiological, RHC 
and clinical information. he North Sheield Ethics Committee 
approved this study and institutional review board approval was 
attained.
All patients with ILD were assessed for radiological disease pattern 
on CT. he most common pathological patterns of ibrosis referred to 
our PH centre are usual interstitial pneumonia (UIP) and non-speciic 
interstitial pneumonia (NSIP). hese groups were prospectively 
separated to examine for diferences between these groups.
cT acquisition
he majority of CTPA scans (76.8%) were conducted at Sheield’s 
Pulmonary Vascular Disease Unit with a further 114 cases performed 
at the referring hospitals in Wales or the North of England. All 
Sheield CTPA cases were performed on a 64-slice MDCT scanner 
(light-speed General Electric Medical Systems, Milwaukee, WI), 
with standard acquisition parameters: 100 mA with automated dose 
reduction, 120 kV, pitch 1, rotation time 0.5 s and 0.625 mm slice 
thickness. A 400 × 400 mm ield of view was used with an acquisition 
matrix of 512 × 512. 100 ml of intravenous contrast agent (Ultravist, 
Bayer, Berlin, Germany) was administered at a rate of 5 ml/sec 
through a wide bore cannula, into a large central vein, typically in 
the ante-cubital fossa. he scan was then timed using a bolus tracking 
technique. HRCT was reconstructed using the contrast-enhanced 
acquisitions with 1.25 mm collimation from the apex of the lung to 
the diaphragm. In order to be included, any CTPA from an outside 
Trust had to be of diagnostic quality, as decided by a radiologist and 
slice thickness ≤5 mm. In the 23.2% (114) CTPAs performed outside 
of Sheield, CT scanner and detailed acquisition parameters were not 
available for reporting.
Mr acquisition
Cardiac magnetic resonance (CMR) imaging was performed on 
a 1.5T whole body scanner GE HDx (GE Healthcare, Milwaukee, 
USA), using an 8-channel cardiac coil. Patients were in the supine 
position with a surface coil and with retrospective ECG gating. A 
retrospective cardiac gated multi-slice balanced steady state free 
precession (bSSFP) sequence was performed orthogonal to the 
main pulmonary artery. he bSSFP sequence parameters were: 
TR 2.8 ms, TE 1.0 ms, Flip angle of 50°, FOV = 48 × 43.2, 256 × 
256 matrix, 125 kHz bandwidth and slice thickness of 10 mm (11).
Pulmonary Function Testing
All patients underwent lung function testing. Percent of predicted 
values for forced vital capacity (FVC), and transfer factor of the 
lungs for carbon monoxide (TLCO) were calculated. he gender, 
age and physiology (GAP) score is a simple tool for estimating 
mortality in ILD from demographic and pulmonary function 
metrics and was calculated as previously described (12).
cT image analysis
Image analysis was carried out on picture archive and 
communication system (PACS) imaging on CE stamped Barco 
Chin et al.
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diagnostic monitors. he observer was blinded to the all other 
clinical and imaging data.
he main pulmonary artery was measured proximal to 
bifurcation, perpendicular to the direction of the vessel at the point 
where largest diameter is most consistent. he ascending aorta 
diameter was also measured on the same CT slice, see Figure 1. 
Right and let pulmonary artery diameters were recorded 1 cm 
from the bifurcation, at their most consistent value. A thoracic 
radiologist scored the severity of ILD on CT, using the Likert semi-
quantitative score, ranging from 0 to 4, 0 = absent, 1 = 1–25%, 2 
= 26–50%, 3 = 51–75%, and 4 = 76–100% involvement (13). he 
imaging subtype of ILD was also recorded (UIP or NSIP).
Mr image analysis
Image analysis was performed on a GE Advantage Workstation 
4.4 and GE Advantage Workstation Report Card. Scans were 
deined as non-diagnostic when image quality signiicantly 
afected cardiac measurements or volumetric analysis could not 
be accurately performed. From the magnitude phase imaging 
images, the maximal (systolic) and minimal (diastolic) PA areas 
were measured, and relative area change (RAC) was deined by 
the following equation: RAC = (maximum area-minimum area)/
minimum area (14, 15).
statistics
he diferences in CT and MRI pulmonary arterial size between 
the patients with and without ILD were analysed using an 
independent t-test for continuous data and the chi-square for 
categorical data. ANOVA with Bonferroni correction was used for 
multiple group comparison. Pearson’s correlation coeicient was 
used to assess the correlation between CT and MRI pulmonary 
arterial measurements and mPAP. Pearson correlations were 
conducted for cohorts of ILD, non-ILD and radiological subtypes 
against CT and MRI derived metric variables. Receiver operating 
characteristic (ROC) analysis was performed to determine 
diagnostic accuracy of CT and MRI pulmonary arterial size 
measurements with area under the ROC curve (AUC) results 
presented. Multiple t-tests were used to assess intergroup 
variance of PA diameter, PA to Aorta (PA:AA) ratio and PA 
relative to body mass index (PA index). he relationship between 
PA diameter with candidate predictors mPAP, ILD severity of 
CT, FVC TLCO, and age, sex and body surface area (BSA) was 
assessed using multivariate linear regression analysis.
Statistical analysis was performed in IBM SPSS Statistics 22 
(SPSS, Chicago) and graphed in GraphPad Prism (GraphPad, San 




From the ASPIRE database 489 patients with suspected PH were 
identiied, including 198 males and 291 females. 420 patients had 
pulmonary hypertension. he mean age for the whole cohort 
was 65 (SD - SD 13). One hundred and ten patients had CT 
features of ILD (101 patients with pulmonary hypertension and 
9 patents without), of which 46 patients had UIP and 43 had 
NSIP radiological subtypes. Chronic EAA (n = 1), asbestosis 
(n = 1), desquamative interstitial pneumonia (n = 1), chronic 
extrinsic allergic, alveolitis (n = 1), silicosis (n = 1), Langerhans 
cell histiocytosis (n = 1), radiotherapy (n = 1) and post infective 
interstitial disease and scarring (n = 4). 379 patients with 
suspected PH had no CT evidence of ILD (319 patients with 
pulmonary hypertension and 60 patients without) as shown in 
Figure 2.  Table 1 provides the baseline demographic data, lung 
function, CT and MRI derived variables for the study cohort as 
a whole and split into the ILD and not ILD cohorts. he mean 
(SD) interval between CT and RHC was 17.6 days (46.1), the 
interval between MRI and RHC was 0.2 days (4.2).
FigUre 1 |  CT images of pulmonary artery diameter measurements in patients with (a) a patient without PH (mean pulmonary arterial pressure of 20 mmHg), (B) 
a patient with PH with moderate elevation in pulmonary arterial pressure (mPAP 54 mmHg). Diameter measured where largest and most consistent - proximal to 
bifurcation, perpendicular to direction of vessel.
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FigUre 2 |  The Study Cohort. PH, pulmonary hypertension; CT, computed tomography scan; MRI, magnetic resonance imaging; MPA, main pulmonary artery; 
CTPA, computed tomography pulmonary angiogram; ILD, interstitial.
TaBle 1 |  Demographic table.
Whole cohort ilD non-ilD p Value*
Mean (sD) N = 489 Mean (sD) N = 110 Mean (sD) N = 379
Demographics 
age 65 (13) 66 (11) 64 (13) 0.656
sex M/F 198/291 37/73 161/218
PH/No PH 420/69 101/9 319/60 0.003
WhO Functional class I/II/III/IV 1/59/378/42 0/9/80/18 1/50/298/24 <0.001
ilD sub-Types UIP/NSIP/Sarcoid/Chronic EAA, 
Other
46/43/11/1/20
right heart catheter 
mRAP (mmHg) 10 (6) 9 (6) 10 (5) 0.017
mPAP (mmHg) 41 (15) 41 (13) 42 (15) 0.856
PAWP (mmHg) 13 (5) 12 (5) 13 (5) 0.014
CI (L/min/m2) 2.7 (0.8) 2.7 (0.8) 2.7 (0.8) 0.981
PVR (dyn.s.m-5) 529.2 (394.3) 539.7 (348.7) 526.1 (408.1) 0.267
Pulmonary function tests 
Predicted FVC % 81.6 72.7 85.0 <0.001
FVC (l) 2.9 (1.1) 2.4 (0.9) 3.1 (1.1) <0.001
Predicted TLCO % 47.9 33.7 52.3 <0.001
TLCO (l) 3.9 (2.0) 2.5 (1.6) 4.3 (2.0) <0.001
cT 
Main PA diameter (mm) 32 (6) 31 (4.9) 32 (5.8) 0.092
PA/AA 1 (0.2) 1 (0.2) 1 (0.2) 0.453
PA/BSA 17.6 (3.5) 18 (3.0) 18 (3.6) 0.434
Right PA diameter (mm) 26 (5) 25 (4.4) 26 (4.7) 0.234
Left PA diameter (mm) 24 (4) 24 (3.4) 25 (4.0) 0.309
Mri 
Systolic PA area (mm2) 920 (306) 887 (269) 930 (316) 0.607
Diastolic PA area (mm2) 833 (276) 807 (255) 814 (281) 0.809
PA relative area (mm2) 10.9 (9.5) 10.6 (7.2) 10.9 (9.3) 0.394
WHO, World Health Organisation; mRAP, mean Right Arterial Pressure; mPAP, mean Pulmonary Arterial Pressure; PAWP, Pulmonary Artery Wedge Pressure; CI, Cardiac Index; 
PVR, Pulmonary Vascular Resistance; TLCO, Transfer Factor of the lungs for Carbon Monoxide; FVC, Forced Volume Capacity.
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group comparisons
Patients with PH had larger pulmonary arteries (33 mm) 
than patients without PH (27 mm) (p < 0.001) In the ILD 
cohort, there was no signiicance between PA size diameters 
in diferent semi-quantitative radiological severity scores of 
ILD, see (Figure  3A, mPAP and ILD severity). here was no 
FigUre 3 |  Correlations between mean PA pressure and PA diameter with pulmonary function tests and CT-derived severity score. Graphs ( a) and (B) represent 
the association with ILD severity on CT in ILD cohort. Graphs (c) and (D) scatter plot showing the association of PA pressure and diameter with TLCO %predicted 
and graphs (e) and (F) scatter plots showing the association of PA pressure and diameter with FVC %predicted.
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diference in mPAP between radiological severities of ILD scores 
(Figure 3B, PA diameter and ILD severity). Furthermore there 
were no signiicant diferences in PA size or diameter between 
CT derived ILD severity within the pathological subgroups, UIP 
p = 0.630 and NSIP p = 1.000.
correlations
CT derived main PA diameter correlated positively with mPAP 
in the ILD cohort (r = 0.608; p < 0.001), which improved when 
the pulmonary artery diameter was indexed to body surface 
area (r = 0.674 ; p < 0.001). MRI derived systolic and diastolic 
pulmonary artery area also correlated signiicantly with mPAP 
in the ILD cohort, (r = 0.423 and 0.479 respectively, p < 0.001). 
In the pathological subtypes, PA diameter correlated with mPAP 
for both UIP (r = 0.592; p < 0.001) and NSIP (r = 0.621; p < 
0.001). Each are shown in Figure 4. In the non-ILD cohort, the 
correlation between mPAP and PA diameter was weaker but 
still signiicant, r = 0.426 (p < 0.001). Table 2 presents Pearson 
correlations for ILD and non-ILD cohorts, with pathological 
UIP and NSIP subtype analysis. In the ILD cohort, there was 
FigUre 4 |  Scatter distribution showing the relationship between mean PA pressure and PA diameter. Subgroups include ILD cohort (a), non-ILD (B), ILD with 
UIP pattern of disease (c) and ILD with NSIP pattern of disease (D).
TaBle 2 |  Correlations of CT and MRI measurements with mean pulmonary arterial pressure.
Pearson correlations to mPaP ilD UiP nsiP non ilD
R Value p Value R Value p Value R Value p Value R Value p Value
cT 
PA Diameter 0.608 <0.001 0.592 <0.001 0.621 <0.001 0.426 <0.001
PA/AA Ratio 0.478 <0.001 0.515 <0.001 0.631 <0.001 0.431 <0.001
PA Index 0.498 <0.001 0.374 0.01 0.674 <0.001 0.402 <0.001
Right PA Diameter 0.466 <0.001 0.396 0.006 0.472 0.002 0.262 <0.001
Left PA Diameter 0.393 <0.001 0.406 0.005 0.656 0.029 0.332 <0.001
Mri 
Systolic PA area 0.423 <0.001 0.461 0.001 0.510 <0.001 0.353 <0.001
Diastolic PA area 0.479 <0.001 0.563 <0.001 0.558 <0.001 0.426 <0.001
PA relative area
change 
−0.397 <0.001 −0.457 0.001 −0.387 0.010 −0.310 <0.001
AA , Ascending Aorta; ILD , Interstitial Lung Disease; mPAP , mean Pulmonary Artery Pressure; NSIP , Non-speciic Interstitial Pneumonia; PA , Pulmonary Artery; UIP , Usual 
Interstitial Pneumonia.
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no signiicant correlation between PA diameter and FVC (r = 
−0.113; p = 0.301) or TLCO (r = −0.041; p = 0.692) respectively, 
as shown in Figure 3 shows the correlations between mean PA 
pressure and PA diameter for ILD (r = 0.608; p < 0.001), non-
ILD (r = 0.461; p < 0.001), UIP (r = 0.592; p < 0.001), NSIP (r 
= 0.595; p < 0.001).
Diagnostic accuracy
Table 3 provides the ROC area under the curve (AUC) values 
for CT and MRI metrics in both ILD and non-ILD cohorts 
for the diagnosis of PH. In the ILD cohort, main PA diameter 
on CT had strong diagnostic accuracy, AUC = 0.873 as did 
systolic and diastolic PA area on MRI (AUC = 0.887 and AUC 
= 0.897, respectively). In addition, high diagnostic accuracy of 
PA diameter on CT, AUC 0.835 and PA systolic and diastolic 
areas (AUC 0.824 and 0.857, respectively) on MRI were found in 
the non-ILD cohort. he relative area change of the pulmonary 
artery during the cardiac cycle was a weaker diagnostic marker 
than pulmonary arterial size.
A previous threshold of 29mm tested in the ILD cohort 
resulted in 75.2% sensitivity, 88.9% speciicity, 98.7% positive 
predictive values and 24.0% negative predictive value. In the non-
ILD cohort, pulmonary arterial diameter was also accurate for 
the diagnosis of PH, with AUC=0.835 (p<0.001). he optimal 
threshold identiied was 30mm, providing 76.3% sensitivity and 
73.3% speciicity. Figure 5 shows the ROC curves for the CTPA 
measured pulmonary arterial diameter  metrics (PA diameter, 
PA:AA ratio and PA index) in both ILD and non-ILD cohorts. 
he highest AUC values for MRI derived variables in the ILD 
cohort (Table 2) were diastolic pulmonary arterial area (0.897) and 
systolic pulmonary arterial area (0.887). MRI variables have shown 
a similar diagnostic accuracy within this study cohort compared 
to CT derived parameters of PA size.
Factors associated with Pulmonary 
arterial size in ilD
At multivariate linear regression analysis, mPAP and body surface 
area were independent predictors of pulmonary arterial size, 
[11.1 + (0.2 × mean pulmonary arterial pressure) + (6.7 × BSA)]. 
Age, sex, GAP score, ILD severity on CT, FVC %predicted and 
TLCO %predicted were not multivariate predictors of pulmonary 
artery diameter (10). Table 4 shows linear regression analysis. 
FigUre 5 |  ROC analysis showing the area under the curve for both ILD (a) and non-ILD (B) cohorts for the CT measured main pulmonary artery size (PA 
diameter and PA:AA Ratio)
TaBle 3 |  Area under the receiver operating characteristic curve for CT and 
MRI pulmonary arterial measurements in ILD and non-ILD cohorts.
cT and Mri Metrics ilD non ilD
aUc p value aUc p value
cT 
Main PA Diameter 0.873 <0.001 0.835 <0.001
PA/AA 0.799 0.003 0.794 <0.001
PA Index 0.595 0.347 0.836 <0.001
Right PA Diameter 0.753 0.012 0.757 <0.001
Left PA Diameter 0.729 0.023 0.754 <0.001
Mri 
Systolic PA area 0.887 <0.001 0.824 <0.001
Diastolic PA area 0.897 <0.001 0.857 <0.001
PA relative area change 0.388 0.266 0.365 <0.001
AA , Ascending Aorta; PA , Pulmonary Artery.
TaBle 4 |  Linear regression analysis, identifying covariates with independent 
association with pulmonary arterial diameter.
Model regression 
co-eficient
se r T statistic p value
(Constant) 11.060 3.471 3.187 0.002
PA Mean 0.205 0.033 0.525 6.168 <0.001
BSA 6.738 1.914 0.300 3.520 0.001
BSA, Body Surface Area; PA, Pulmonary Artery.
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Mean pulmonary arterial diameter had an adjusted correlation 
coeicient of 0.575 (p < 0.001) and BSA of 0.249 (p = 0.001).
DiscUssiOn
In this retrospective study of 491 patients with suspected pulmonary 
hypertension referred to a tertiary referral centre, we show that 
main pulmonary arterial diameter has similar diagnostic utility in 
patients with and without ILD. In our cohort, pulmonary arterial 
diameter is independently associated with mean pulmonary 
arterial pressure and body size. he size of the pulmonary artery 
was not independently inluenced by semi-quantitative radiological 
severity score of ILD, FVC, TLCO, or GAP score.
It has been postulated that in patients with pulmonary ibrosis 
the pulmonary artery dilates in the absence of elevated pulmonary 
arterial pressure, as consequence of architectural distortion of 
the lung parenchyma. In contrast, in this cohort of patients, 
we have found that pulmonary arterial diameter is diagnostic 
of pulmonary hypertension in ILD, to a similar accuracy as 
seen in patients with pulmonary hypertension who do not have 
ILD (AUC 0.874 for ILD cohort and AUC 0.835 for non-ILD 
cohort), irrespective of the underlying radiological ILD pattern. 
UIP is typiied by signiicant parenchymal distortion, including 
honeycombing, traction bronchiectasis and volume loss (16), 
therefore if PA size is driven by architectural destruction in ILD, 
it should be apparent in this group. However, PA size remains 
more closely associated with PH metrics than quantitative 
metrics of ILD severity in patients with UIP. In addition, the 
optimal pulmonary arterial diameter threshold for prediction 
of elevated mean pulmonary artery pressure was relatively low 
in patients with ILD at 29 mm, similar to 30 mm for patients in 
the non-ILD cohort. Mean pulmonary arterial diameter in our 
ILD cohort with pulmonary hypertension was 32 mm, compared 
to a mean of 25 mm in patients with ILD without pulmonary 
hypertension.
As expected, TLCO and FVC were lower in the patients with 
ILD than those without. However, the ILD and non-ILD cohorts 
were well-matched in terms of PH severity, as deined by their 
RHC metrics. he clinical and radiological markers of ILD 
severity (TLCO, FVC and CT semi-quantitative severity score) had 
weak correlations with pulmonary arterial diameter (r = −0.148, 
p = 0.174/r = −0.153, p = 0.138/r =0.082, p = 0.393 respectively). 
Furthermore, there is a strong correlation between PA diameter 
and mean PA pressure within the ILD cohort (r = 0.608). On 
multivariate linear regression, the clinical and radiological 
markers of disease severity were not independent predictors of 
pulmonary arterial size. In fact, the independent predictors were 
body surface area and pulmonary arterial pressure.
Both CT and MRI derived pulmonary arterial size metrics were 
assessed. MRI variables showed high diagnostic accuracy with both 
systolic and diastolic pulmonary arterial area having diagnostic 
utility in both ILD and non-ILD cohorts. MRI derived diastolic 
pulmonary arterial area, was the most accurate diagnostic variable 
across the whole study cohort, regardless of the presence of ILD. 
Diastolic pulmonary arterial size was of systematically marginally 
higher diagnostic accuracy than systolic. We postulate that this is 
because of greater pulsatility of the pulmonary artery of a patient 
without pulmonary hypertension, allowing the pulmonary artery to 
reduce in size in diastole to a greater extent relative to a patient with 
pulmonary hypertension.
PA size measured on MRI also correlated well with RHC derived 
mean pulmonary arterial pressure and showed similar diagnostic 
accuracy to CT derived PA diameter. his trend was similar in both 
patients with and without interstitial lung disease. A limitation 
of routine CT pulmonary angiography is lack of cardiac gating; 
MRI with cardiac gating has provided additional proof of the 
equivalent utility of PA diameter in interstitial lung disease and 
non- interstitial lung disease
he pulmonary artery can dilate over time in a patient with 
elevated pulmonary arterial pressure (17). Hence the absolute 
instantaneous measure of pulmonary arterial pressure in a patient 
with pulmonary hypertension will be dependent not only on the 
pressure but also the duration of the disease, which explain the 
variable correlation observed between pulmonary arterial size 
and pressure in patients with suspected PH (5–7, 11, 18–20). All 
patients were referred with suspected pulmonary hypertension, 
however it is unknown how long the pressure has been elevated, 
given the insidious onset of the disease, absolute quantiication of 
duration of disease is challenging.
liMiTaTiOns
his study is limited by its retrospective design at a single 
tertiary referral centre, although in order to reduce bias from 
the retrospective analysis, the cohort is made up of consecutive 
patients. As this was performed in a pulmonary hypertension 
referral centre, there is a bias towards the presence of PH and as 
such there are only a few patients with no PH, so these results 
are only valid in the setting of a PH referral centre. It is expected, 
however that the strong correlation between mPAP and PA size 
in this cohort of patients would be similar in a non-selected 
patient cohort. A study in a non-PH centre, in a cohort with 
more even distribution of patients with and without pulmonary 
hypertension would be of beneit.
Interstitial lung diseases are a heterogeneous group of diseases 
with idiopathic and known-cause aetiologies. We have grouped the 
largest cohorts of ibrotic ILDs here to explore if the architectural 
destruction of UIP had a greater inluence on PA dilatation than 
NSIP, but in practice these are not clinical diagnoses. However, in 
practice these are the patterns most likely to lead to ibrotic-driven 
architectural distortion and so we have taken a pragmatic approach 
in separating these. Further work evaluating the impact of varying 
forms of ILD, such as scleroderma related and drug induced ILD on 
the pulmonary vasculature, in terms of PA size and haemodynamic 
changes would be of value.
cOnclUsiOn
Pulmonary arterial pressure elevation leads to pulmonary arterial 
dilation, which is not independently inluenced by the presence or 
severity of ILD measured by FVC, TLCO, or disease severity on CT. 
Chin et al.
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Pulmonary arterial diameter has diagnostic value in patients with 
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